Seven Eli Lilly Stock Buys Worth Up to $680,000 Surface
Seven eli lilly stock purchases worth up to $680,000 were made on Donald Trump's behalf from 6 January through the end of March 2026, even as federal actions widened access to obesity drugs linked to the company. For investors, the filings tie a president's portfolio activity to policy decisions that touched one of the drugmaker's key growth areas.
Trump's 2026 Lilly Trades
$680,000 was the top end of the value attached to seven acquisitions of Eli Lilly shares made on Trump's behalf in the first quarter of 2026. The disclosures also showed several thousand trades tied to stocks and bonds during that period, with a cumulative value ranging from $220 million to about $750 million.
6 January marked the start of the Eli Lilly buying window, and the transactions ran through the end of March 2026. KFF Health News highlighted the purchases, which sit alongside trades in some of the largest US companies, including Apple, Boeing, Goldman Sachs, Meta Platforms, Microsoft and Nvidia.
TrumpRx and Medicare Access
February 2026 brought TrumpRx, a direct-to-consumer drug sales website aimed at lowering prescription drug costs. A White House fact sheet said the service initially featured medications made by the first five manufacturers that struck pricing deals with the administration, including Eli Lilly, and pointed patients to LillyDirect, the company's telemedicine service.
Earlier this week, the White House expanded TrumpRx to more than 600 generic medications. At the same time, the Centers for Medicare and Medicaid Services said it will expand access to GLP-1 medications, including Lilly's Foundayo and Zepbound KwikPen, for Medicare patients.
Discretionary Accounts and Control
The Trump Organization said the president's investment holdings are maintained through fully discretionary accounts independently managed by third-party financial institutions. The organization also said neither President Trump, his family nor the Trump Organization plays any role in selecting, directing or approving specific investments. They receive no advance notice of trading activity and provide no input regarding investment decisions or portfolio management of any kind.
For readers tracking the stock, the friction point is not the purchase count alone. The filings show trades on behalf of a sitting US president during a period when federal agencies were expanding access to products that support Eli Lilly's obesity-drug business, leaving the policy and portfolio timelines tightly overlapped.
